GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off
Britain’s GSK (GSK.L) forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in its first earnings report since rejecting Unilever’s (ULVR.L) bid for its consumer arm.
